Background {#Sec1}
==========

Solitary fibrous tumours (SFT) are soft tissue neoplasms of mesenchymal origin first described in 1931 by Klemperer and Rabin \[[@CR1]\]. They are typically found in the pleura but are ubiquitously distributed and have been reported to originate from a number of extrapleural sites. Solitary fibrous tumours of the liver (SFTL) are rare, with only 84 reported cases in the English literature (PubMed + Google + publication references) including the present case. Most SFTLs are benign but there have been a handful of reports on malignant cases, some of which have had local recurrences and metastatic spread.

Diagnosis is typically made with histopathological findings and immunohistochemical examination of resected samples. Preoperative investigation of SFTLs can be difficult with non-specific radiological features. Biopsy of radiological liver lesions remains controversial due to the risk of inconclusive results \[[@CR2], [@CR3]\] or seeding of the biopsy tract \[[@CR4]\]. Given the malignant potential of these tumours, surgical resection is the preferred method of treatment if possible.

This report is only the third described case of its kind in the English literature, a malignant SFTL with extensive local recurrence and metastatic spread 6 years following clear resection margins.

Main text {#Sec2}
=========

Case presentation {#Sec3}
-----------------

A 61-year-old male was referred to the emergency department by his general practitioner in April 2010 for investigation of loose bowel motions and an episode of black stool. The patient had a history of insulin-dependent type II diabetes mellitus, hypertension, ischaemic heart disease with two previous ischaemic events, obstructive sleep apnoea, depression, schizophrenia and a previous incisional hernia repair.

On examination, he was morbidly obese (BMI 45) and was noted to have marked hepatomegaly. This was not associated with any recent weight loss, haematemesis, jaundice or abdominal pain. The patient denied previous blood transfusions, usage of intravenous drugs and did not drink alcohol. A faecal occult blood test was negative, and the patient's last colonoscopy 2 years prior was unremarkable.

He was referred to our tertiary centre for further management after an ultrasound scan (USS) displayed an ovoid mass of mixed echogenicity arising from the liver, measuring 12 × 9 cm. A computed tomography (CT) scan confirmed a malignant appearing, pedunculated lesion attached to segment IV (Fig. [1](#Fig1){ref-type="fig"}). A subsequent magnetic resonance imaging (MRI) confirmed that on T2 weighted imaging (WI), the lesion was isointense to the liver peripherally with central branching hyperintensities (Fig. [2a](#Fig2){ref-type="fig"}) which corresponded to the hypointensities seen on T1WI (Fig. [2b](#Fig2){ref-type="fig"}). Enhancement of the lesion was noted in arterial phase (Fig. [3a](#Fig3){ref-type="fig"}), during portal venous phase (Fig. [3b](#Fig3){ref-type="fig"}) and at 2 min (Fig. [3c](#Fig3){ref-type="fig"}), with some central areas of non-enhancement. The lesion becomes slightly hypointense on delayed images at 10 (Fig. [3d](#Fig3){ref-type="fig"}) and 20 min compared to the surrounding liver.Fig. 1Abdominal CT displaying the pedunculated liver lesion arising from segment IV Fig. 2Abdominal MRI displaying the liver lesion. **a** T2WI. **b** T1WI Fig. 3MRI T1WI after contrast. **a** Arterial phase. **b** Portal venous phase. **c** Delayed 2 min. **d** Delayed 10 min

Laboratory investigations revealed a mildly elevated gamma-glutamyl transpeptidase of 137 IU/L (normal 5--50 IU/L). Hepatitis screen, alpha-fetoprotein, carcinoembryonic antigen and cancer antigen 19--9 were all unremarkable.

The patient underwent a subsegmental resection of the 15 cm segment IVb mass in June 2010. There was severe hepatic steatosis, but no cirrhosis. The patient was discharged postoperative day seven without complications.

Pathology of the resection specimen confirmed SFTL. The specimen displayed a pale tan nodular appearance with a firm and rubbery cut surface. Histological examination revealed fascicles of spindle cells in storiform arrangement with a pushing margin. There was evidence of extracellular collagen deposition, areas of myxoid stroma and branching vessels with hyalinisation. The specimen displayed a high mitotic rate of up to 9 per 10 high-power fields (HPF) with no necrotic or haemorrhagic features. Immunohistochemistry showed positive staining for CD34, CD99 and BCL-2. The tumour was negative for c-Kit, CD31, SMA, desmin, cytokeratins (AE1/AE3, MNF116 and Cam 5.2), EMA and S100. The margins were clear. The non-neoplastic remainder of the liver displayed pericellular fibrosis indicative of steatohepatitis.

The patient was followed-up regularly every 4 to 6 months with CT scans by the local general practitioner who liaised with the consultant surgeon. There were two episodes of re-admissions for further investigation of recurrent right upper quadrant pain between 2011 and 2013. Multiple MRI scans performed during this period revealed expected postsurgical changes with no tumour recurrence. However, in May 2016, the patient presented to his local emergency department with progressively worsening right upper quadrant pain and increasing dyspnoea with an oxygen demand. CT of his chest, abdomen and pelvis revealed extensive tumour recurrence adjacent to the previous resection site (Fig. [4](#Fig4){ref-type="fig"}). In addition, there was a clinically significant right-sided pleural effusion and a pleural mass at the right lung base measuring 3.8 cm (Fig. [5](#Fig5){ref-type="fig"}).Fig. 4CT abdomen of recurrent disease adjacent to resection site. **a--b** Axial views. **c**--**d** Transverse views Fig. 5CT chest transverse view displaying right-sided pleural mass associated with significant unilateral pleural effusion

Pleurocentesis was performed, draining 1400 ml of serosanguineous fluid. Cytology was negative for malignant cells. The case was discussed extensively in a multi-disciplinary setting, and it was decided given the patient's two sites of disease and significant perioperative risk that he was not a candidate for radical reoperation. There were also no suitable chemo- or radiotherapeutic therapies available. The patient was subsequently referred to the palliative team for management of his symptoms and discharged back to the community. He was still alive 1 month after discharge.

Discussion {#Sec4}
==========

SFTs are fibroblastic neoplasms first described in 1931 \[[@CR1]\] that are of mesenchymal origin and typically arise from the pleura. Initially thought to be of mesothelial origin, they have been historically referred to as benign mesothelioma, localised fibrous mesothelioma and pleural fibromas \[[@CR5]\]. Their extrapleural involvement and ubiquitous nature have been well described over the last century with publications documenting primary cases arising from the respiratory tract \[[@CR6]\], orbit \[[@CR7]\], thyroid \[[@CR8]\], adrenal gland \[[@CR9]\], spinal cord \[[@CR10]\], meninges \[[@CR11]\], breasts \[[@CR12]\], peritoneum \[[@CR13]\], pancreas \[[@CR14]\] and soft tissues \[[@CR15]\].

SFTs involving the liver are exceptionally rare with only 84 cases reported in the English literature since 1958 (Table [1](#Tab1){ref-type="table"}). The average age of patients is 57.1 (range 16--87) and appears to occur in females more than males (1.4:1). Most SFTLs follow a benign course, however, 17.9% (*n* = 15) of cases displayed malignant histological features.Table 1Clinical summary of SFTL cases found in English literatureNo.AuthorYearAgeSexLobeSize (cm)HypoTreatmentIHCFollow-up1Edmondson et al. \[[@CR57]\]195816FR23 × 17NResectionn/a24 months2n/an/aR5 × 5NResectionn/an/a3Nevius and Friedman \[[@CR36]\]195956MR15 × 15YRadiationn/aDied after 2 days4Ishak et al. \[[@CR58]\]197662ML24NResectionn/an/a562FL23 × 20 × 13NResectionn/aIntraoperative death6Kim and Damjanov \[[@CR29]\]198327FL27 × 23 × 15NResectionn/a6 months7Kottke-Marchant et al. \[[@CR47]\]198984FL15 × 9 × 8NResectionV+29 months8Kasano et al. \[[@CR59]\]199139FL18 × 10 × 18NResectionn/a53mo9Barnoud et al. \[[@CR49]\]199650MR17 × 15 × 11NResectionCD34+, V+n/a10Levine et al. \[[@CR60]\]199757ML10 × 18 × 8NResectionCD34+, V+38 months11Guglielmi et al. \[[@CR27]\]199861FR20 × 16 × 10YResectionCD34+, V+72 months12Licesne et al. \[[@CR61]\]199869FLn/aNResectionCD34+, V+12 months13Bejarano et al. \[[@CR16]\]199849ML17 × 12 × 10NResectionCD34+, V+15 months14Moran et al. \[[@CR17]\]199862Fn/a23 × 20 × 13NResectionCD34+, V+n/a1534Fn/a2 × 0.5NNiln/aIncidental (autopsy)1657Fn/a24 × 19 × 11NResectionCD34+, V+n/a1732Mn/a12 × 9 × 7NResectionCD34+, V+n/a1868Fn/a17 × 17NResectionCD34+, V+Died day 2 postop1983FR18YResectionCD34+, V+Died day 6 postop2072FL9NResectionCD34+, V+12 months2162ML24NResectionCD34+, V+n/a2250Fn/a3 × 2 × 1.5NResectionCD34+, V+n/a23Fuksbrumer et al. \[[@CR18]\]200040FR14--17NResectionCD34+, V+, bcl-2+n/a2471FR14--17NResectionCD34+, V+, bcl-2+n/a2580MR14--17NNilCD34+, V+, bcl-2+n/a26Yilmaz et al. \[[@CR30]\]200025FR32 × 30NResectionV+6 months27Lin et al. \[[@CR37]\]200175MR21 × 20 × 18YResectionCD34+11 months28Gold et al. \[[@CR62]\]2002n/an/an/an/aNn/an/an/a29n/an/an/an/aNn/an/an/a30Neeff et al. \[[@CR63]\]200463FR30 × 12 × 19NResectionCD34+, V+6 months31Chithriki et al. \[[@CR32]\]200476FR20 × 15 × 16YResectionCD34+, bcl-2+11 months32Vennarecci et al. \[[@CR19]\]200565MR30 × 28 × 14NResectionCD34+, V+30 months33Moser et al. \[[@CR34]\]200573FR35 × 20 × 15YResectionCD34+, V+, bcl-2+n/a34Ji et al. \[[@CR22]\]200642FR6 × 5 × 5YResectionCD34+n/a35Lehmann et al. \[[@CR64]\]200663FRn/aNResectionCD34+96 months36Nath et al. \[[@CR44]\]200661FR21 × 14.5 × 30NResectionCD34+, V+10 months37Terkivatan et al. \[[@CR28]\]200674ML24 × 21 × 15NResectionCD34+, CD99+, V+, bcl-2+12 months38Chan et al. \[[@CR35]\]200770MR27 × 24 × 12YResectionCD34+, CD99+, V+, bcl-2+9 months39Obuz et al. \[[@CR39]\]200752ML10 × 11 × 12NResectionCD34+, V+22 months40Perini et al. \[[@CR65]\]200740FLn/aNResectionCD34+, V+49 months41Weitz et al. \[[@CR66]\]2007n/an/an/an/aNResectionn/an/a42n/an/an/an/aNNiln/an/a43n/an/an/an/aNNiln/an/a44Kandpal et al. \[[@CR67]\]200845FRn/aNResectionCD34+n/a45Fama et al. \[[@CR31]\]200868MRn/aYResectionCD34+, V+25 months46Korkolis et al. \[[@CR3]\]200882FL18 × 15 × 8NResectionCD34+, V+, bcl-2+, desmin+21 months47Chen et al. \[[@CR2]\]200871MR8.7 × 5.5 × 8.5NResectionCD34+, CD99+, bcl-2+9 months48El-Khouli et al. \[[@CR43]\]200868FL + R15 × 10.5 × 13NTACECD34+, V+n/a49Hoshino et al. \[[@CR21]\]200930FR6.7 × 4.5 × 4NNilCD34+, bcl-2+6 months50Novais et al. \[[@CR50]\]201034FR25 × 23 × 13NResectionCD34+, V+24 months51Brochard et al. \[[@CR51]\]201054MR17NResectionCD34+, V+, desmin+, actin+72 months52Haddad et al. \[[@CR25]\]201062MLn/aNResectionCD34+n/a5345FR7.4 × 5.9 × 5.4NResectionCD34+, V+, bcl-2+n/a54Park et al. \[[@CR68]\]201051FLn/aNResectionn/an/a55Peng et al. \[[@CR52]\]201124FR30 × 17 × 15NResectionCD34+, V+, bcl-2+Died at 16 months56Sun et al. \[[@CR69]\]201159ML9 × 7 × 6NResectionCD34+, CD99+, V+, bcl-2+24 months57Patra et al. \[[@CR26]\]201234FL14.5 × 10 × 8NResectionCD34+, V+, bcl-2+48 months58Radunz et al. \[[@CR33]\]201285FLn/aYResectionCD34+, bcl-2+n/a59Belga et al. \[[@CR70]\]201266FRn/aNResectionCD34+30 months60Morris et al. \[[@CR53]\]201223FR27 × 23.5 × 4NResectionCD34+, V+, bcl-2+10 months61Beyer et al. \[[@CR45]\]201246MRLig21 × 7NHRT + chemo + resectionCD34+10 months62Soussan et al. \[[@CR42]\]201364MLn/aNResectionCD34+, bcl-2+n/a63Liu et al. \[[@CR71]\]201342ML1.5 × 1 × 1NResectionCD34+, bcl-2+n/a64Jakob et al. \[[@CR72]\]201362FLn/aNResectionCD34+, CD99+, bcl-2+n/a65Debs et al.\[[@CR73]\]201365MLn/aNResectionCD34+, CD99+, bcl-2+12 months6687FR14.6 × 12.3 × 17NNiln/a10 months67Durak et al. \[[@CR55]\]201338FL8 × 6 × 2NResectionCD34+, CD99+, SM actin+n/a68Vythianathan and Long \[[@CR74]\]201378ML17 × 13NResectionCD34+, CD99+, V+, bcl-2+n/a69Song et al. \[[@CR75]\]201449ML + R7.6 × 5 × 4.8NResectionCD34+, V+, bcl-2+3 months70Texeira Jr et al. \[[@CR76]\]201468FL7.5 × 6.5 × 5.5NResectionCD34+, V+28 months71Du et al. \[[@CR56]\]201555FL11 × 17 × 15YResectionCD34+, bcl-2+60 months72Beltran \[[@CR77]\]201558ML15 × 9 × 6NResectionCD34+, V+36 months73Bejarano et al. \[[@CR40]\]201579FR15NTACE + resectionCD34+, V+, bcl-2+31 months74Feng et al. \[[@CR20]\]201551MR2.3 × 0.3NResectionCD34+, bcl-2+11 months7549ML8.7NResectionCD34+, V+, bcl-2+17 months7651FR8.4NResection + adjuvant chemoCD34+, V+, bcl-2+31 months7752FR12NResection + MWACD34+, V+37 months78Silvanto et al. \[[@CR24]\]201565ML18NResectionCD34+, CD99+, bcl-2+16 months79Kueht et al. \[[@CR23]\]201540ML4.7 × 4 × 4NResectionCD34+, CD99+, V+, bcl-2+n/a80Maccio et al. \[[@CR46]\]201574FR24 × 16NResectionCD34+, V+, bcl-2+, STAT6+Died at 15 months8180FR19 × 15NChemotherapyCD34+, V+, bcl-2+, STAT6+Died at 4 months8265MR3 × 2NChemotherapyCD34+, V+, bcl-2+, STAT6+Died at 5 months83Makino et al. \[[@CR78]\]201555MR8.6 × 6.3NResectionCD34+, CD99+, bcl-2+11 months84Present case201661MR15 × 11.5 × 7.5NResectionCD34+, CD99+, bcl-2+74 months*Hypo* hypoglycaemia, *IHC* immunohistochemistry, *F* female, *M* male, *L* left, *R* right, *N* no, *Y* yes, *n/a* not available, *RLig* round ligament, *TACE* transarterial chemoembolisation, *chemo* chemotherapy, *HRT* hormone replacement therapy, *MWA* microwave ablation

The clinical presentation of SFTL is generally non-specific, ranging from weight loss and fatigue to upper abdominal fullness \[[@CR16]\] or discomfort due to the tendency of these tumours to be quite large. In many cases, SFTLs are found incidentally during routine examination \[[@CR17]--[@CR22]\] or on routine imaging while investigating other pathologies \[[@CR2], [@CR23]--[@CR25]\]. Patients may also present with symptoms secondary to compression of visceral or neurovascular structures adjacent to the mass such as dyspepsia \[[@CR26]\], postprandial pain/nausea/vomiting \[[@CR22], [@CR27]--[@CR29]\] or jaundice \[[@CR30]\]. There is no specific laboratory or tumour marker for SFTL, and serum investigations are generally non-informative. A small percentage of patients (13.1%) however, present with paraneoplastic syndromes such as non-islet cell tumour hypoglycaemia \[[@CR31]\] associated with extrinsic production of high-molecular weight insulin-like growth factor II (IGF-II) which spontaneously resolves after resection of the mass \[[@CR17], [@CR19], [@CR24], [@CR30]--[@CR37]\]. There does not appear to be an association between hypoglycaemic presentations and malignant cases (*n* = 1). These IGF-II associated SFTs have also been documented in cases involving the pleura and so are not limited to SFTLs \[[@CR38]\].

Preoperative diagnosis is difficult due to non-specific radiological findings. Sonography often reveals a heterogeneous mass which may be either or both hypo- and hyperechogenic with or without calcifications. A contrast-enhanced CT characteristically shows early arterial enhancement with delayed venous washout \[[@CR3], [@CR22]\]. Findings on MRI are similar to that of CT scans. In T1WI, the SFTL demonstrates a heterogeneous mass with hypointense signals compared to the normal hepatic parenchyma which is thought to reflect the high content of collagenous tissue \[[@CR39], [@CR40]\]. A heterogeneous mass that may be both hypo- and hyperintense is observed in T2WI with some areas described as almost isointense to cerebrospinal fluid \[[@CR18], [@CR41]\]. On images post-gadolinium-based contrast injection, SFTLs display progressive heterogeneous enhancement starting in the arterial phase corresponding to the hypervascular areas and persisting into the venous and delayed phases, likely due to the collagen-rich interstitium \[[@CR42]\]. There does not appear to be any features on either USS, CT or MRI that differentiates between benign or malignant disease without a tissue diagnosis.

Percutaneous biopsy for tissue diagnosis prior to resection is a much debated topic but is a well-documented approach in the lead up to the resection of SFTLs \[[@CR3], [@CR16], [@CR18], [@CR27], [@CR28], [@CR31], [@CR40], [@CR43]--[@CR47]\]. Given the many risks it poses---including seeding the tumour via the needle tract \[[@CR4], [@CR48]\], pain, intrahepatic or subcapsular haematoma and bile leaks \[[@CR4]\]---it is doubtful whether preoperative biopsy would change management if the lesion is able to be safely resected \[[@CR24]\]. Fuksbrumer et al. \[[@CR18]\] describes a case which showed histological changes suggesting low-grade malignant transformation which was not discovered in the initial biopsy while Korkolis et al. \[[@CR3]\] reports a case of SFTL whose initial biopsy was indicative of hepatocellular carcinoma. A third report by Chen et al. \[[@CR2]\] presents a case in which a biopsy suggested metastatic pancreatic or upper gastrointestinal tract lesion in a patient with a history of colorectal adenocarcinoma prior to resection. Postoperative histological examination indicated SFTL and disproved the preoperative diagnosis.

Diagnosis is limited to histopathological and immunohistochemical investigations. Macroscopic examination of SFTLs appears to be relatively consistent amongst all cases in this literature review. SFTLs range in size, measuring from 0.5 \[[@CR17]\] to 35 cm \[[@CR34]\]. They tend to be grey-white or tan-yellow in colour and are well-circumscribed, nodular and encapsulated by a smooth glistening capsule, often continuous with the Glisson's capsule \[[@CR27], [@CR47], [@CR49]\]. On the cut surfaces, they are well documented to be firm and difficult to cut with a whorled bulging appearance interspersed with central areas of scarring and radiating bands of fibrous tissue. Some SFTLs may also display features of myxoid degeneration \[[@CR3], [@CR22], [@CR26], [@CR40], [@CR50]\], necrosis \[[@CR20], [@CR27], [@CR28], [@CR35], [@CR42], [@CR51], [@CR52]\], haemorrhage \[[@CR20], [@CR51]\] or cystic cavitation \[[@CR2], [@CR24], [@CR29], [@CR34], [@CR35], [@CR40], [@CR42], [@CR53]\].

Microscopically, they are composed of ovoid spindle-shaped cells with little cytoplasm within a characteristic storiform or haphazardly 'pattern-less pattern' architecture. These cells are distributed between alternating hypo- and hypercellular areas separated from each other by thick bands of keloid-like collagen bundles and branching of staghorn vessels resembling a haemangiopericytoma-like pattern. Myxoid changes were also commonly observed \[[@CR17], [@CR26]\]. Mitoses are rare and generally limited to malignant cases, as is necrosis and cytological atypia. Most cases displayed mitoses \<4/10HPF. In 2002, the World Health Organization (WHO) revised their classification of tumours and recognised SFTs as a fibroblastic/myofibroblastic tumour and identified it as a separate entity to haemangiopericytomas. Features identified by WHO to be associated with malignancy include hypercellularity, cytologic atypia, tumour necrosis, infiltrative margins and high mitotic activity (≥4/10 HPF) \[[@CR54]\].

There are no specific immunohistochemical profiles for SFTL, however, there are a few markers which are characteristic such as CD34 which has shown strong reactivity in all documented cases as well as CD99, BCL-2 and Vimentin which do not appear as sensitive. Durak et al. \[[@CR55]\] reports an interesting case in which there was a strong positivity for CD34 and CD99 but similarly for smooth muscle actin and focal weak positivity for oestrogen and progesterone receptors in the spindle cells which has not been documented before. Few cases report immunoreactivity to desmin \[[@CR3], [@CR51]\] (*n* = 2) and actin \[[@CR51], [@CR55]\] (*n* = 2). SFTLs are otherwise typically negative for c-Kit (CD117), CD31, cytokeratins, EMA, factor VIII, epithelial membrane antigen and S100.

On literature review, there appears to be sixteen cases documenting malignant SFTLs (Table [2](#Tab2){ref-type="table"}), local recurrence or distant metastases. 17.9% (*n* = 15) of patients were diagnosed with malignant SFTL based on the histology reports. The average age of these patients was 59.6 years with almost equal distribution between males and females (7:8). Of these cases, 26.7% (*n* = 4) were noted to have local recurrence (9 months--6 years) and 53% (*n* = 8) to have distant metastasis (1 month--6 years). This compared similarly to intrapleural SFTs with recurrence rates of 20--67% in malignant tumours \[[@CR35]\].Table 2SFTL cases with malignant features, local recurrence or metastatic diseaseNo.Author (year)Age/sexRec/MetPresentationLobeSize (cm)Mass (g)TreatmentHistopathologyTumour markersIHCFollow-up1Fuksbrumer et al. (2000) \[[@CR18]\]71/FNiln/aR14--17n/aResection (UM)Dense cellularity, increased nuclear atypia, mitoses 8/10 HPFn/aCD34+, bcl-2+, V+n/a2Yilmaz et al. (2000) \[[@CR30]\]25/FMetWeakness, fatigue, anorexia, vomiting and progressive jaundiceL + R32 × 304500Resection (UM)Cellularity ranged from 20--60%, necrosis, hypervascularityNADV+Bone metastasis 1 month postsurgery managed with 6 months of chemo (cyclophosphamide, adriamycin)3Chan et al. (2007) \[[@CR35]\]70/MRec + MetHypoglycaemia and progressive jaundiceR27 × 24 × 124400Failed TACE 6 weeks preoperatively followed by successful resection (UM)Mildly atypical spindle cells, highly cellular, plemorphia, necrosis, mitoses \> 20 HPFCA-125 145U/ml (normal \< 35 U/ml)CD34+, CD99+, bcl-2+, V+Asymptomatic widespread bilateral lung metastasis and bi-lobar recurrence at 9 months review4Brochard et al. (2010) \[[@CR51]\]54/MRec + MetRUQ pain and weight lossR17n/aResection (FM)Moderately cellular, polymorphic cells, mitoses \< 5/10 HPFGGT 438 IU/ml (normal \< 45 U/ml)CD34+, V+, desmin+, actin+Local recurrence 6 years postsurgery managed with resection (findings: necrotic, haemorrhagic, highly cellular, moderately atypical nuclei, mitoses \>20/10 HPF, CD34, bcl-2. Negative for desmin and actin).\
Cranial base metastasis managed by embolization and resection. Retroperitoneal and iliac bone metastasis weeks later, patient died 1 month after5Peng et al. (2011) \[[@CR52]\]24/FMetRUQ discomfort and distentionR30 × 17 × 153750TACE few days prior to resection (FM).Highly cellular, pleomorphic, necrosis, mitoses \> 10/HPFCA-125 abnormalCD34+, bcl-2+, V+Craniotomy 13 days postsurgery for skull base metastases with large residual lesion. Vertebral metastasis 1 month later managed with 4× PEI and 4 rounds of chemo (adriamycin, ifosfamide, mesna). Tumour relapsed and rapidly enlarged with paralysis on 7 months review, patient died 16 months after initial surgery6Belga et al. (2012) \[[@CR70]\]66/FNilIncrease in abdominal girthR14n/aResection (UM)Mitoses \> 4/10 HPF, necrosis, mild nuclear atypiaNADCD34+30 months7Jakob et al. (2013) \[[@CR72]\]62/FNilUpper abdominal pain and weight lossLn/an/aResection (UM)High cellularity, cytological atypia, necrosis, mitoses 6/10 HPFNADCD34+, CD99+, bcl-2+n/a8Vythianathan and Yong (2013) \[[@CR74]\]78/MNilEpigastric painL17 × 13n/aResection (UM)Cellular pleomorphism, necrosis, mitoses \> 4/10 HPFn/aCD34+, CD99+, bcl-2+, V+n/a9Song et al. (2014) \[[@CR75]\]49/MNilAbdominal painL + R7.6 × 5 × 4.8n/aResection (UM)NADn/aCD34+, bcl-2+, V+n/a10Du et al. (2015) \[[@CR56]\]55/FRecHypoglycaemia and weight lossL15.3 × 15.5 × 15.4n/aResection (UM)n/aNADCD34+, bcl-2+Local recurrence 5 years postsurgery, resected11Feng et al. (2015) \[[@CR20]\]52/FRecn/aR12n/aResection (UM)Haemorrhage, necrosisNADCD34+Local recurrence 2 years postsurgery on L lobe managed with PEI. New lesion 6 months after PEI12Silvanto et al. (2015) \[[@CR24]\]65/MNilIncidental findingL18n/aResection (lesion 1--2 mm from margins)Myxoid changes, infarction, necrosis mitoses 5--7/10 HPFNADCD34+, CD99+, bcl-2+16 months13Maccio et al. (2015) \[[@CR46]\]74/FMetRight abdominal pain and distensionR24 × 16n/aResection (FM)Nuclear pleomorphism, cytological atypia, necrosis, haemorrhage, mitoses 9/10 HPFn/aCD34+, bcl-2+, V+, STAT6+Lung, omentum, mesentery and abdominal wall metastasis at 9 months review managed with chemotherapy---patient died 4 months later14Maccio et al. (2015) \[[@CR46]\]80/FMetDyspnoea, cough, asthenia, abdominal painR19 × 15n/aPalliative chemotherapyHighly cellular, pleomorphism, necrosis, haemorrhage, mitoses 7/10 HPFn/aCD34+, bcl-2+, V+, STAT6+R lung metastasis managed with palliative chemotherapy---patient died 5 months later15Maccio et al. (2015) \[[@CR46]\]65/MMetAbdominal discomfort, vomiting and painR3 × 2n/aChemotherapyCytological atypia, necrosis, mitoses \> 6/10 HPFn/aCD34+, bcl-2+, V+, STAT6+Bilateral lung metastasis managed with chemotherapy, patient died 5 months later16Present case (2016)61/MRec + MetDiarrhoeaR15 × 11.5 × 7.5n/aResection (FM)Myxoid changes, mitoses \> 9/10 HPFNADCD34+, CD99+, bcl-2+Extensive local recurrence and pleural metastases 6 years later---palliatively managed. Remains alive 1 month after discharge*Rec* recurrence, *Met*: metastasis, *IHC* immunohistochemistry, *M* male, *F* female, *L* left, *R* right, *n/a* not available, *UM* unknown margins, *FM* free margins, *HPF* high-power fields, *TACE* transarterial chemoembolization, *RUQ* right upper quadrant, *NAD* no abnormality detected, *PEI* percutaneous ethanol injection, *V* vimentin

Only three cases \[[@CR35], [@CR51]\] including the current case are reported to have both local recurrence and metastasis but no significant features to foresee this could be identified in this data. All three were male and their average age was 61.7 years. The size of tumours ranged from 11 to 27 cm and two of the three cases had high rates of mitoses (\>9/10 HPF). It is interesting to note that Du et al. \[[@CR56]\] reports a case on a 55-year-old female with non-malignant SFTL who represented 5 years after initial surgery with local recurrence and associated hypoglycaemia which resolved spontaneously after resection. The tumour did not display any marked variances when compared to other non-malignant SFTLs.

Surgical resection remains the mainstay of treatment for SFTLs and appears to be the cure for most cases where histopathology returns showing a benign lesion with a clear resection margin of \>1 cm. There is very little literature on the use of radio- and chemotherapy, and its efficacy in the long-term is unknown given the scant experience with these approaches. El-Khouli et al. \[[@CR43]\] describes a case of SFTL treated with three sessions of transarterial chemoembolisation (TACE) for an inoperable lesion. They describe a favourable outcome on the basis of increased intratumoral necrosis, reduced tumoural enhancement and stabilisation of tumour size based on consecutive MRI scans. Beyer et al. \[[@CR45]\] describes a case where the SFTL was initially thought to be a desmoid tumour, and the patient was managed with hormone replacement therapy before imatinib was trialled with no effect. The patient eventually underwent surgical resection with no malignant features evident. Feng et al. \[[@CR20]\] presents a case series with one patient undergoing adjuvant chemotherapy (mitomycin) due to extensive tumour infiltration of multiple vascular structures and another patient who was trialled on percutaneous microwave coagulation therapy and percutaneous ethanol injection for local recurrence without success as new lesions were found 6 months later on follow-up. Maccio et al. \[[@CR46]\] reports a case series where two patients underwent chemotherapy for SFTL with metastatic spread to the lungs without success as both patients died within 5 months.

Prognosis for SFTLs is unknown and difficult to measure due to the little experience and understanding of the biological nature of the disease. The rarity of this tumour makes it hard to gather enough cases for a study on alternative treatment options, and the absence of long-term follow-up also hinders on the evaluation of patient outcome over long-periods for both benign and malignant cases. The use of adjuvant radio- and/or chemotherapy as well as TACE is scarcely reported and so its efficacy cannot be commented on. It would be valuable to review these patients several years down the track to see how their disease has progressed.

Conclusion {#Sec5}
==========

SFTL is a rare neoplasm that should be considered in the differential diagnosis of patients presenting with vague abdominal symptoms secondary to compression of adjacent structures due to a large hepatic mass. Radiological findings are often non-specific and are unable to differentiate between a benign or malignant mass and percutaneous biopsies are not recommended if the tumour is considered resectable. Complete surgical resection is, thus, the recommended treatment of choice and curative in most cases as the risk for malignant transformation and metastatic spread is not unheard of. Careful long-term follow-up is suggested as prognosis is uncertain for these lesions. This case provides yet another example of the malignant potential of SFTLs to recur locally and metastasise to distant locations.
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